CRITERIA OF ANTIBACTERIALS CHOICE FOR PROPHYLAXIS AND THERAPY OF IMPLANT-ASSOCIATED INFECTIONS IN PROSTHETIC JOINTS
Abstract
Prosthetic joints infection in after is a serious medical, social and financial problem. Significant achievements in prophylaxis of such infections are well known. In cases of primary endoprosthetics of large joints, the frequency of infection in the leading world clinics is 0.5-2%. However, the approaches to the treatment of such infections are different especially with respect to the antibacterial therapy: choice of drugs, administration routes, treatment course and discontinuation. Under conditions of global growth of resistance in nosocomial pathogens, the choice of antimicrobials requires consideration not only of the formal susceptibility criteria, but also of the pharmacokinetic and pharmacodynamic indices.
About the Authors
N. V. Petrova
Novosibirsk Research Institute of Traumatology and Orthopedics
Russian Federation
Russian Federation
V. P. Shevchenko
Novosibirsk Research Institute of Traumatology and Orthopedics
Russian Federation
Russian Federation
V. V. Pavlov
Novosibirsk Research Institute of Traumatology and Orthopedics
Russian Federation
Russian Federation
V. M. Prokhorenko
Novosibirsk Research Institute of Traumatology and Orthopedics
Russian Federation
Russian Federation
V. N. Golnik
Novosibirsk Research Institute of Traumatology and Orthopedics
Russian Federation
Russian Federation
References
1. Прохоренко В. М. Инфекционные осложнения при эндопротезировании тазобедренного сустава: монография / В. М. Прохоренко, В. В. Павлов. Новосибирск: 2010; 179.
2. Kurd M. F., Ghanem E., Steinbrecher J., Parvizi J. Two-stage exchange knee arthroplasty: does resistance of the infecting organism influence the outcome? Clin Orthop Rel Res 2010; 469: 8: 2060-2066.
3. Прохоренко В. М., Павлов В. В., Петрова Н. В. Классификация и диагностика инфекции области хирургического вмешательства при эндопротезировании тазобедренного сустава. Вестн травматол ортопед 2010; 1: 39-43.
4. Peel T. N., Buising K. L., Choong P. F. M. Prosthetic joint infection: challenges of diagnosis and treatmentans. ANZ J Surg 2011; 81: 32-39.
5. Wolf C. F., Gu N. Y., Doctor J. N. at al. Comparison of one and two-stage revision of total hip arthroplasty complicated by infection. JBJS Am 2011; 93: 7: 631-639.
6. Прохоренко В. М., Павлов В. В., Петрова Н. В. Профилактика, диагностика и лечение ранней инфекции области хирургического вмешательства при эндопротезировании тазобедренного сустава. Травматол ортопед России 2008; 2: 48: 84-90.
7. Della Valle C., Parvizi J., Bauer T. V. et al. AAOS clinical practice guideline on diagnosis of PJI. JBJS Am 2011; 93: 14: 1355-1357.
8. William J. Gillespie Prevention and Management of Infection After Total Joint Replacement URL: http://cid.oxfordjournals.org February 11, 2012
9. EUCAST Clinical Breakpoint Table v. 2.0, valid from 2012-01-01/ URL: http://www.eucast.org.
10. Cunha B. A. Antibiotic tissue penetration. Bull N Y Acad Med 1983; 59: 5: 443-449.
11. Slavik R. S., Jewesson P. J. Selecting antibacterials for parenteral antimicrobial therapy: pharmacokinetic-pharmacodynamic considerations. Clin pharmacokinet 2003; 42: 9: 793-817.
12. Widmer A. F. et al. Correlation between in vitro and in vivo efficacy of antimicrobial agent against foreing body infections. J Infect Dis 1990; 162: 1: 96-102
13. Darley E. S., MacGowan A. P. Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 2004; 53: 6: 928-935.
14. Kienapfel H., Kuhr K. D. The infected implant / Springer. 2009. 87.
15. Graziani A. L. et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988; 32: 9: 1320-1322.
16. Guidelines for ATC classification and DDD assignment 2012 / WHO collaborating centre for drug statistics methodology / URL http://www.whocc.no/filearchive/publications/2012_guidelines_with _front_pa.pdf
17. Определение чувствительности микроорганизмов к антибактериальным препаратам. Методические указания. МУК 4.2.1890-04. Клин микробиол антимикроб химиотер 2004; 6: 4: 306-359.
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Seventeenth informational supplement. CLSI Document M100-S17. 2007; 27: 1.
19. Vancomycin rationale for the EUCAST Clinical Breakpoint, v. 2.1 valid from 2010-17-06/ URL. http://www.eucast.org.
Review
For citations:
Petrova N.V., Shevchenko V.P., Pavlov V.V., Prokhorenko V.M., Golnik V.N. CRITERIA OF ANTIBACTERIALS CHOICE FOR PROPHYLAXIS AND THERAPY OF IMPLANT-ASSOCIATED INFECTIONS IN PROSTHETIC JOINTS. Antibiot Khimioter = Antibiotics and Chemotherapy. 2012;57(3-4):45-49. (In Russ.)
Views:
503
Email this article 